Related Experiment Video
Updated: Nov 17, 2025
11:27
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
17.0K
Immune checkpoint blockade in renal cell carcinoma
Phillip M Rappold1, Andrew W Silagy1, Ritesh R Kotecha2
1Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Journal of Surgical Oncology
|February 17, 2021
Summary
Immune checkpoint blockade (ICB) offers long-lasting remission for metastatic renal cell carcinoma (mRCC). New biomarkers are crucial for selecting the best ICB therapies and understanding surgery's role in mRCC treatment.
Area of Science:
- Oncology
- Immunology
- Nephrology
Background:
- Immune checkpoint blockade (ICB) is a cornerstone therapy for metastatic renal cell carcinoma (mRCC).
- ICB therapies offer the potential for durable responses in mRCC patients.
- The increasing number of ICB options necessitates better patient selection strategies.
Purpose of the Study:
- To review current data on ICB efficacy in RCC.
- To discuss emerging biomarkers predictive of ICB response.
- To explore the role of surgery in the context of mRCC and ICB.
Main Methods:
- Literature review of clinical trials and studies on ICB in RCC.
- Analysis of data on biomarkers associated with ICB response.
- Evaluation of surgical approaches in mRCC management.
Main Results:
- ICB has demonstrated significant efficacy in mRCC, leading to long-term remissions.
- Several biomarkers are under investigation for predicting ICB response.
- The role of surgery is being redefined alongside advancements in systemic therapy.
Conclusions:
- Biomarkers are essential for personalizing ICB treatment in mRCC.
- A comprehensive understanding of ICB, biomarkers, and surgery is vital for optimizing mRCC care.
Related Concept Videos
02:34Inhibition of Cdk Activity
5.3K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
01:27Tumor Immunotherapy
860
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
860
02:57Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.0K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.0K